SIC
AVEO

Samalin Investment Counsel’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Samalin Investment Counsel’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-100
Closed – – 560
2019
Q4 		$0 Buy
+100
New +$736 ﹤0.01% 561

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
XSC
X-Square Capital Guaynabo, Puerto Rico $297M AUM 32.87% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Samalin Investment Counsel's AVEO Position: Q1 2020 in Review

Samalin Investment Counsel sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2020, closing a stake of 100 shares.

Samalin Investment Counsel first reported a position in AVEO in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 35 funds tracked by Wall St. Rank hold AVEO as of Q1 2020.

  • Samalin Investment Counsel reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Samalin Investment Counsel sold 100 AVEO Pharmaceuticals, Inc. shares in Q1 2020.
  • Samalin Investment Counsel first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • Samalin Investment Counsel's AVEO Pharmaceuticals, Inc. position peaked at $0 in Q4 2019.
  • 35 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2020.

Based on Samalin Investment Counsel's 13F filing for Q1 2020, filed 4 May 2020.